logo

For the Inventor, By the Inventor

Ibaraki, Japan

Makoto Inoue

This inventor holds 10 USPTO granted patents and 11 published patent applications and 1 EPO patent. Top assignees: Dna Vec Research Inc., International Aids Vaccine Initiative, Dnavec Corporation. Active years: 2006-2020.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Makoto Inoue. Retrieved from https://idiyas.com/inventor/makoto-inoue-t0doba40

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 10 

% Patents Active = 50.0


Average Co-Inventor Count = 5.8

ph-index = 3

Forward Citations = 17(Granted Patents)


Company Filing History:

goldMedal6 out of 31 
 
Dna Vec Research Inc.
 patents
silverMedal2 out of 72 
 
International Aids Vaccine Initiative
 patents
bronzeMedal1 out of 5 
 
Dnavec Corporation
 patents
4. 1 out of 9 
 
Id Pharma Co., Ltd.
 patents
5. 1 out of 834,601 
Other
 patents
where one patent can have more than one assignee

Years Active: 2006-2020

Loading Chart...
Loading Chart...
10 patents (USPTO):Explore Patents
1. 10792357 - Optimized HIV envelope gene and expression thereof (2020-10-06),
2. 10220087 - Optimized HIV envelope gene and expression thereof (2019-03-05),
3. 10017784 - Gene transfer into airway epithelial stem cell by using lentiviral vector pseudotyped with RNA virus or DNA virus spike protein (2018-07-10),
4. 8741650 - Methods for producing minus-strand RNA viral vectors using hybrid promoter comprising cytomegalovirus enhancer and chicken β-actin promoter (2014-06-03),
5. 8283163 - Method for production of dendritic cell (2012-10-09),
6. 7709621 - Vectors with modified protease-dependent tropism (2010-05-04),
7. 7521043 - Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines (2009-04-21),
8. 7402427 - Vectors with modified protease-dependent tropism (2008-07-22),
9. 7226786 - Envelope gene-deficient Paramyxovirus vector (2007-06-05),
10. 7144579 - Paramyxoviruses comprising modified transcription start sequence (2006-12-05),

Title: Innovator Makoto Inoue: Pioneering Advances in HIV Research

Introduction

Makoto Inoue, a distinguished inventor based in Ibaraki, Japan, has made substantial contributions to the field of biotechnology. With a remarkable portfolio of 10 patents, his pioneering work focuses primarily on optimizations related to HIV research and vaccine development.

Latest Patents

Among his latest innovations, Inoue has developed a series of patents pertaining to the optimized HIV envelope gene and its expression. The key invention involves a vector containing and expressing an optimized HIV EnvF gene, which encompasses methods for creating cell substrates that are qualified for vaccine production. This development signifies a significant stride toward more effective HIV vaccines, potentially transforming the landscape of treatment and prevention for this global health issue.

Career Highlights

Throughout his career, Makoto Inoue has been affiliated with prominent organizations, including Dna Vec Research Inc. and the International AIDS Vaccine Initiative. His tenure at these institutions has reinforced his dedication to advancing scientific research and developing innovative solutions in the fight against HIV.

Collaborations

Inoue has collaborated with notable professionals in the field, including Mamoru Hasegawa and Akihiro Iida. These partnerships have undoubtedly contributed to his inventive endeavors, fostering an environment of shared knowledge and expertise.

Conclusion

As an inventor, Makoto Inoue continues to push boundaries in HIV research. His ongoing commitment to innovation and collaboration signifies his important role in the advancement of medical science, offering hope for an improved understanding and management of HIV.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…